Magnesium Glycinate vs Vitamin K2 (MK-7)

Mechanism

Magnesium is a cofactor for >600 enzymatic reactions including all ATP-dependent reactions (Mg-ATP is the true substrate), DNA/RNA polymerases, and ion channel regulation. Magnesium glycinate chelate provides highly bioavailable elemental magnesium bound to glycine. The glycine moiety itself is an inhibitory neurotransmitter (glycine receptors) and NMDA receptor co-agonist at the glycine binding site. The chelated form minimizes the osmotic laxative effect of ionic magnesium salts. Magnesium regulates NMDA receptor gating (voltage-dependent Mg2+ block), GABA-A receptor potentiation, HPA axis modulation, and parathyroid hormone secretion.

Standard Dosing

200-400mg elemental magnesium daily

Timing

Evening/bedtime (promotes relaxation and sleep quality). Can split AM/PM.

Cycle Duration

ongoing

Side Effects

• Drowsiness
• Mild GI discomfort
• Loose stools (less than other Mg forms)
• Hypotension at very high doses

Contraindications

• Severe renal insufficiency (impaired Mg excretion — risk of hypermagnesemia)
• Myasthenia gravis (Mg can worsen neuromuscular junction blockade)
• Heart block (Mg slows AV conduction)

Best Stacking Partners

Mechanism

Vitamin K2 (menaquinone-7) activates vitamin K-dependent proteins via gamma-carboxylation of glutamic acid residues. Key targets: osteocalcin (directs calcium into bone matrix), matrix Gla protein (MGP, inhibits arterial calcification), Gas6 (cell signaling, neuroprotection), and protein S (anticoagulant). MK-7 has a long half-life (~72 hours vs 1-2 hours for K1) enabling consistent carboxylation activity with once-daily dosing. It works synergistically with Vitamin D3 to regulate calcium metabolism — D3 increases calcium absorption while K2 directs its deposition.

Standard Dosing

100-200 mcg MK-7 daily

Timing

With fat-containing meal alongside Vitamin D3.

Cycle Duration

ongoing (mandatory co-supplement with Vitamin D3)

Side Effects

• Generally very well tolerated
• Rare: mild GI discomfort
• Theoretical thrombotic risk in deficiency-rebound scenario (unproven)

Contraindications

• Warfarin/coumarin anticoagulant therapy (unless specifically directed by physician with INR monitoring)

Best Stacking Partners